David P. Frazier Ph.D.

Partner

David Frazier focuses his practice primarily on patent litigation, strategic pre-litigation client counseling, due diligence analyses, and providing opinions in the fields of biotechnology, vaccines, and pharmaceuticals.

Dr. Frazier has broad experience in a wide variety of litigation and pre-litigation matters, including preparing for, litigating, and trying Abbreviated New Drug Application (ANDA) litigation and traditional patent litigation in the areas of biopharmaceuticals and bioinstrumentation. Dr. Frazier also has broad experience in due diligence evaluations in connection with patent acquisition and licensing transactions.

Highlights

• Represented biotechnology company at trial in action to determine first true inventors of a therapeutic protein.
• Represented branded pharmaceutical companies in Hatch-Waxman litigation, including pretrial, trial, and settlement.
• Represented branded pharmaceutical companies in strategic analyses and preparation for Hatch-Waxman litigation.
• Represented branded pharmaceutical companies in defense against infringement claims relating to molecular mechanisms of action.
• Represented branded pharmaceutical company in patent enforcement actions against compounding pharmacies.
• Represented biotechnology and pharmaceutical companies in due diligence analyses related to technology in-licensing opportunities and business acquisitions.

Professional Recognition

• Order of the Coif

Professional Activities

• American Bar Association
• Federal Circuit Bar Association
• American Intellectual Property Association
• American Association for the Advancement of Science

Select Publications

Coauthor. "Surviving an Obviousness Patent Challenge," Drug Discovery & Development, Oct. 27, 2008.
• Coauthor. "Litigating Patent Obviousness," Bio IT World, Oct. 2008.